Azurity Pharma Inc v. Appco Pharma LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Azurity Pharmaceuticals, Inc. (Delaware)
  • Defendant: Appco Pharma LLC (Delaware) and Somerset Therapeutics, LLC (Delaware)
  • Plaintiff's Counsel: Potter Anderson & Corroon LLP
• Case Identification: 1:26-cv-00402, D. Del., 04/08/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendants are organized under the laws of Delaware and are thus deemed to reside in the district.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's ZONISADE® product constitutes an act of infringement of three patents related to oral liquid formulations of zonisamide.
• Technical Context: The technology concerns pharmaceutical compositions, specifically stable, liquid oral suspensions of the anticonvulsant drug zonisamide, designed for patients who have difficulty swallowing solid dosage forms.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendants' submission of ANDA No. 220352. The complaint states that on February 24, 2026, Defendants provided a notice letter regarding their ANDA filing. The patents-in-suit are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") in connection with Plaintiff's New Drug Application for its ZONISADE® product.

Case Timeline

Date	Event
2017-08-19	Priority Date for '456, '333, and '179 Patents
2022-10-25	U.S. Patent No. 11,478,456 Issued
2022-12-20	U.S. Patent No. 11,529,333 Issued
2025-12-09	U.S. Patent No. 12,491,179 Issued
2026-02-24	Defendants Send Notice Letter Regarding ANDA Filing
2026-04-08	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,478,456 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

The Invention Explained

• Problem Addressed: The patent's background section notes that the anticonvulsant drug zonisamide is typically available in solid dosage forms like capsules and tablets '456 Patent, col. 3:9-11 It identifies a need for an oral liquid dosage form for patients, such as young children or the seriously ill, who have difficulty swallowing solid forms '456 Patent, col. 3:1-7
• The Patented Solution: The invention is a liquid pharmaceutical suspension of zonisamide designed for oral administration '456 Patent, abstract The formulation combines zonisamide with a specific set of pharmaceutically acceptable excipients, including suspending agents, buffering agents, preservatives, and sweetening agents, to achieve a composition that is both stable and palatable '456 Patent, col. 4:21-37
• Technical Importance: Developing a stable and palatable liquid suspension of a drug previously available in solid form can improve patient compliance and expand therapeutic access to patient populations unable to take pills '456 Patent, col. 3:1-7

Key Claims at a Glance

• The complaint asserts infringement of "one or more claims" of the '456 Patent Compl. ¶35 Independent claim 1 is a method of use claim.
• Independent Claim 1: A method of treating seizures by administering a liquid oral pharmaceutical suspension with specific properties:
  • Contains zonisamide in an amount of "about 20 mg/mL"
  • Contains a dual suspending agent system: "about 2 mg/mL to about 3.5 mg/mL xanthan gum" and "about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose"
  • Contains "one or more buffering agents"
  • Contains "a preservative"
  • Has a "pH of 3.5 to 5.0"
  • Is "stable for at least 6 months when stored at 40° C. and 25% relative humidity"

U.S. Patent No. 11,529,333 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

The Invention Explained

• Problem Addressed: Similar to the '456 Patent, this patent addresses the challenge that some patients cannot swallow the solid oral dosage forms in which zonisamide is conventionally available, necessitating a liquid alternative '333 Patent, col. 3:6-9
• The Patented Solution: The patent describes an oral liquid suspension of zonisamide '333 Patent, abstract The solution employs a carefully selected combination of excipients-including specific suspending agents (xanthan gum and a cellulose combination), buffering agents, and a preservative-to maintain the drug in a stable suspension within a defined pH range, making it suitable for oral administration '333 Patent, col. 4:18-34
• Technical Importance: The invention provides a means of delivering zonisamide therapy to a broader patient population by creating a stable, ready-to-use liquid formulation '333 Patent, col. 4:7-14

Key Claims at a Glance

• The complaint asserts infringement of "one or more claims" of the '333 Patent Compl. ¶40 Independent claim 1 is a composition of matter claim.
• Independent Claim 1: A liquid oral pharmaceutical suspension comprising:
  • Zonisamide "in an amount of about 20 mg/mL"
  • A suspending agent comprising "about 2 mg/mL to about 3.5 mg/mL xanthan gum" and "about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose"
  • "one or more buffering agents"
  • "one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients comprise a preservative"
  • A "pH of 3.5 to 5.0"
  • A stability requirement where the composition is "stable for at least 6 months when stored at 40° C. and 25% relative humidity"

U.S. Patent No. 12,491,179 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

The Invention Explained

• Technology Synopsis: This patent addresses the need for a liquid oral formulation of the anticonvulsant zonisamide for patients who cannot swallow solid pills '179 Patent, col. 3:5-10 It discloses a stable oral suspension comprising zonisamide, specific suspending agents, buffering agents, a preservative, sucralose, and strawberry flavor, all maintained within a specific pH range to ensure stability and palatability '179 Patent, abstract '179 Patent, Claim 1

Key Claims at a Glance

• Asserted Claims: The complaint asserts infringement of "one or more claims" Compl. ¶45 Independent claim 1 is a composition claim.
• Accused Features: The accused features are the composition and properties of the Defendants' ANDA Product, a generic oral suspension of zonisamide intended to be a substitute for Plaintiff's ZONISADE® product Compl. ¶1 Compl. ¶28 Compl. ¶32

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is the generic zonisamide oral suspension described in Defendants' Abbreviated New Drug Application (ANDA) No. 220352 (the "ANDA Product") Compl. ¶1 Compl. ¶28

Functionality and Market Context

• The complaint alleges that the ANDA Product is a generic version of Azurity's ZONISADE®, an FDA-approved anticonvulsant for adjunctive therapy in treating partial onset seizures Compl. ¶1 Compl. ¶14 By filing the ANDA, Defendants have represented to the FDA that their product has the same active ingredient, route of administration, dosage form, use, and strength as ZONISADE®, and that it is bioequivalent Compl. ¶32
• The ANDA Product is intended for commercial manufacture, use, and sale in the United States upon receiving FDA approval, positioning it as a direct competitor to Plaintiff's branded product Compl. ¶30

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or specific technical details mapping the ANDA Product to the patent claims. The infringement allegation is statutory, arising from the act of filing an ANDA under 35 U.S.C. § 271(e)(2)(A) Compl. ¶35 Compl. ¶40 Compl. ¶45 The core of this allegation is that by seeking approval for a generic equivalent of ZONISADE®-for which the patents-in-suit are listed in the FDA's Orange Book-Defendants have necessarily proposed a product that will infringe one or more claims of those patents upon approval Compl. ¶36 Compl. ¶41 Compl. ¶46 The detailed comparison between the ANDA product's formulation and the claim limitations will be a central subject of discovery.

• Identified Points of Contention:
  • Scope Questions: The dispute may center on the construction of claim terms defining the composition's quantitative and functional properties. Key questions could include:
    • What is the permissible range of concentrations covered by the term "about" as it is applied to zonisamide and the various excipients?
    • What specific metrics (e.g., impurity levels, physical characteristics) are required to satisfy the limitation that the suspension is "stable for at least 6 months" under the specified conditions?
  • Technical Questions: A primary factual dispute will be whether the precise formulation of the Defendants' ANDA Product, once disclosed, meets every element of the asserted claims. This raises the question of what evidence will show that the ANDA Product contains the claimed dual-component suspending agent system at the specified concentrations and exhibits the required pH and stability profile.

V. Key Claim Terms for Construction

The complaint does not identify specific claim terms for construction. However, based on the language of the independent claims of the '456 and '333 patents, the following terms may become central to the dispute.

• The Term: "about" (e.g., "about 20 mg/mL," "about 3.5 mg/mL")

  • Context and Importance: This term modifies nearly every concentration value in the independent claims. Its interpretation will be critical for determining the boundaries of the claims and whether the ANDA product literally infringes. Practitioners may focus on this term because even a small deviation in the ANDA product's concentration could evade infringement if "about" is construed narrowly.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification does not provide an explicit definition for "about," which may support applying its ordinary meaning of "approximately" or "reasonably close to." The use of the term suggests the inventors did not intend the claims to be limited to the exact numerical values recited.
    • Evidence for a Narrower Interpretation: The patents provide examples with precise concentrations, such as "Zonisamide 20.00 mg/ml" '456 Patent, col. 8, Table 1 A party could argue that these embodiments constrain the meaning of "about" to a very narrow range around the stated values.

• The Term: "stable for at least 6 months when stored at 40° C. and 25% relative humidity"

  • Context and Importance: This functional limitation sets a required performance standard for the claimed suspension. The determination of infringement will depend on whether the Defendants' product meets this stability benchmark.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification includes tables with stability data showing that an exemplary formulation maintained low levels of impurities over six months '456 Patent, col. 9, Table 2 '456 Patent, col. 10, Table 4 A party may argue that "stable" should be interpreted in light of these examples, meaning the formulation does not significantly degrade chemically.
    • Evidence for a Narrower Interpretation: A party could argue that "stable" implies more than just chemical stability, potentially encompassing physical properties such as viscosity, particle suspension, and resistance to microbial growth. The patent mentions preventing the growth of microorganisms as a goal, which could be tied to the definition of stability '456 Patent, col. 5:5-7

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Defendants' commercial activities will induce infringement by others Compl. ¶36 This allegation is based on the proposed product labeling, which will instruct physicians and patients to use the ANDA Product for the patented method of treating seizures Compl. ¶41 The complaint also asserts there are no substantial non-infringing uses for the ANDA Product Compl. p. 9, lines 1-3
• Willful Infringement: The complaint alleges that Defendants had "actual and constructive knowledge" of the patents-in-suit prior to filing their ANDA and demonstrated "specific intent to infringe" by filing the ANDA Compl. ¶37 Compl. ¶42 Compl. ¶47 This allegation is based on the statutory framework of the ANDA process, which requires generic applicants to address patents listed in the Orange Book.

VII. Analyst's Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two central questions that bridge claim interpretation and factual evidence.

• A core issue will be one of definitional scope: How broadly will the court construe quantitative claim terms modified by "about" and the functional requirement of being "stable"? The outcome of this construction will set the legal boundaries for infringement.
• A key evidentiary question will be one of compositional identity: Does the specific formulation detailed in the Defendants' confidential ANDA submission, once revealed through discovery, contain every ingredient at every concentration and exhibit every performance characteristic (e.g., pH, stability) required by the court's interpretation of the asserted claims?